Vericel (VCEL) Other Working Capital Changes (2010 - 2026)
Vericel (VCEL) posted Other Working Capital Changes of $188000.0 for Q2 2026, down 23.58% sequentially from $246000.0 in Q1 2026, and up 109.68% YoY from $89662.2 in Q2 2025.
Vericel (VCEL) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Vericel has reported Other Working Capital Changes for 17 years, with the latest figure at $188000.0 in Q2 2026.
- Quarterly Other Working Capital Changes rose 109.68% year-over-year to $188000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 million (up 1020.98% YoY) and the FY2025 annual result came in at $457000.0, up 5.3% from the prior year.
- Other Working Capital Changes retreated to -$111000.0 in Q3 2019 per VCEL's latest filing, from $141000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $141000.0 in Q2 2019 and troughed at -$158000.0 in Q2 2018.
- A 5-year average of $21857.1 and a median of $37000.0 in 2015 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 450.57% in 2024, down 366.47% in 2024.
- Over 5 years, Other Working Capital Changes stood at $51000.0 in 2015, then tumbled by 147.06% to -$24000.0 in 2016, then plunged by 33.33% to -$32000.0 in 2017, then surged by 456.25% to $114000.0 in 2018, then tumbled by 197.37% to -$111000.0 in 2019.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$111000.0, $141000.0, and $46000.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188,000.00 |
| Jun 30, 2026 | 188,000.00 |
| Jun 30, 2026 | 188,000.00 |
| Mar 31, 2026 | 246,000.00 |
| Mar 31, 2026 | 246,000.00 |
| Mar 31, 2026 | 246,000.00 |
| Dec 31, 2025 | -262,000.00 |
| Dec 31, 2025 | -262,000.00 |
| Dec 31, 2025 | -262,000.00 |
| Sep 30, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Dec 31, 2024 | -595,000.00 |
| Dec 31, 2024 | -595,000.00 |